No New Safety Signals Seen With Migraine Prevention Drug

(MedPage Today) -- DENVER -- No new safety signals emerged with daily atogepant (Qulipta) for migraine prevention, an interim analysis of a long-term safety extension study showed, and improvements in efficacy were sustained. After an average...
Source: MedPage Today Neurology - Category: Neurology Source Type: news